Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

NCT02660528 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Study staff change.

Conditions

Major Depressive Disorder

Interventions

DRUG: Tocilizumab

Sponsor

Brigham and Women's Hospital